Correction issued for zanubrutinib plus R-CHOP in DLBCL phase II study
Nature has published a correction to the phase II study of zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with a specific gene alteration. The correction is narrow but important: the updated version of figure 2 was not included during the correction process, and the original article has now been corrected.
In a field where treatment decisions can hinge on a single Kaplan-Meier curve, a dosing schema, or a biomarker-linked response figure, even a seemingly small graphic omission can affect how readers interpret the data record. For a phase II lymphoma study, the figure set often carries much of the visual evidence supporting efficacy, safety, and subgroup interpretation. When an updated figure is missing, the paper’s textual content may remain intact, but the visual presentation of the trial is incomplete.
Why figure corrections matter in lymphoma research
Diffuse large B-cell lymphoma is a biologically heterogeneous disease, and studies focused on specific gene alterations aim to narrow therapy to patients most likely to benefit from a targeted strategy layered onto standard immunochemotherapy. In that setting, figures are not decoration. They are part of the scientific argument.
A corrected figure can alter how investigators, hematologists, and oncology researchers read the balance between response and risk, even when no new efficacy or safety claims are introduced. In a phase II design, readers are often examining early signals rather than definitive practice-changing proof. The visual elements of the article therefore shape whether the data appear coherent, internally consistent, and ready for later confirmation in larger studies.
The correction published on 5 November 2026 identifies a specific production problem rather than a clinical reinterpretation. No new endpoint, enrollment figure, adverse-event signal, or response estimate appears in the correction notice itself. The substance of the update is editorial and graphical: the article now includes the revised figure that had been omitted.
That may sound modest, but oncology literature depends on precision at the level of panels, axes, and annotations. When a study is built around a molecularly defined subgroup, a figure can encode how that subgroup behaved across time, how treatment arms diverged, or how investigators summarized the data visually for the journal record. An omission in that setting is not trivial, because readers often rely on the figures to validate the narrative in the text.
The trial question remains centered on biologically selected diffuse large B-cell lymphoma
The original study addressed previously untreated diffuse large B-cell lymphoma with a specific gene alteration, evaluating zanubrutinib combined with R-CHOP in a phase II framework. Although the correction notice does not restate the clinical outcomes, the therapeutic premise remains easy to recognize: pair a Bruton tyrosine kinase inhibitor with standard chemoimmunotherapy in a genomically defined lymphoma subset where pathway dependence could plausibly influence treatment sensitivity.
That strategy fits a broader movement in hematologic oncology toward matching drug mechanism to tumor biology. In DLBCL, molecular heterogeneity has long complicated uniform treatment approaches. A targeted agent layered onto an established backbone is meant to improve disease control without abandoning the regimen that has historically anchored first-line therapy.
For clinicians, the corrected figure matters because it restores the completeness of the published evidence trail. For investigators, it preserves the integrity of the study presentation before the article is cited, discussed in tumor boards, or used as background for future trial design. For readers tracking the emerging role of zanubrutinib in lymphoma, the correction ensures the article now reflects the intended final version.
One sentence captures the practical consequence: the paper was amended because an updated figure had been left out.
Editorial precision as part of clinical transparency
Corrections in oncology journals can look procedural, but they are a key part of scientific stewardship. Clinical research is cumulative, and later studies often inherit not just the conclusions of earlier work, but the formatting, figures, and subgroup framing that help define the next question. If a figure version is wrong or absent, downstream interpretation can become messy quickly, particularly when the study has direct relevance to treatment selection in a molecularly defined lymphoma population.
The correction notice names the original paper, the journal, the publication date, and the fact that the article has been corrected. It also identifies the corresponding authors and confirms that the update concerns figure 2. No broader erratum is described. There is no evidence in the notice of altered conclusions, changed patient data, or revised safety interpretation.
That restraint is meaningful. It suggests the issue was limited to presentation rather than the underlying scientific claims. In oncology publishing, such limited corrections still deserve attention because they protect the accuracy of the literature without overstating their clinical impact. Readers need to know whether a correction changes the message or simply restores the intended version of the article. Here, the notice points to the latter.
What clinicians and researchers should take from the correction
For hematologists and oncology researchers following targeted approaches in DLBCL, the immediate takeaway is straightforward: the phase II article on zanubrutinib plus R-CHOP has been updated, and the corrected version now includes the missing revised figure 2. The correction does not introduce new clinical findings, but it does close a gap in the published record.
In a disease area where treatment strategies are increasingly stratified by biology, publication accuracy has real value. It affects how a study is cited, how its visuals are read in conference settings, and how confidently investigators use it when shaping the next protocol. A figure omission may not change the trial itself, but it can change the fidelity of the public record.
The next meaningful step for this line of research will not come from the correction notice. It will come from the larger body of evidence needed to determine how well zanubrutinib-based combinations perform in biomarker-selected diffuse large B-cell lymphoma, and whether the apparent rationale holds up in more mature and more definitive datasets.